Company Milestones and Financial Performance - PROCEPT BioRobotics achieved significant milestones, including Medicare reimbursement in 2021 and FDA clearance of the HYDROS System in 2023[12, 15] - The company's global revenue reached $224.5 million in 2024 and projects revenue guidance of $323 million[15, 18] - The company completed a $150 million equity follow-on and a $175 million equity follow-on[14, 15] HYDROS System and Market Penetration - The HYDROS Robotic System is resonating with all BPH hospital segments, driving market awareness[31, 34] - U.S. install base has shifted towards higher volume hospitals, with high-volume hospitals representing 61% of the install base in 1Q25, compared to 20% in 1Q23[30] - The company is on pace to become the 2 hospital-based resective BPH procedure in the U.S[18] Aquablation Therapy and Clinical Practice - Kansas City Urology & Oncology (KCUC) has increased annual BPH procedure volumes by 42% since 2021[56] - Dr Park's annual Aquablation procedures at KCUC doubled, demonstrating a 124% growth[58] - Aquablation therapy has increased surgical conversion rates from 10% to 25% due to more objective evaluation[62] Prostate Cancer and Aquablation Therapy - Approximately 26% of localized prostate cancer diagnoses are high risk, 50% are intermediate risk, and 24% are low risk[79] - Early data from PRCT001 + PRCT002 trials includes 88 prostate cancer patients treated, with 47 patients having 6-month follow-up data[125] - 70% of prostate cancer patients in PRCT001 + PRCT002 trials have intermediate-risk disease[127] - Single center data suggests Aquablation may delay cancer progression, with a 30% progression avoidance at 5 years compared to active surveillance[168]

Key Milestones & Financials - PROCEPT BioRobotics achieved global revenue of $224.5 million in 2024[15] - The company's revenue guidance for 2025 is $323 million[18] - In 2021, PROCEPT BioRobotics had an IPO at $1.2 billion market capitalization[12] HYDROS System & Commercial Update - HYDROS resonates with all BPH hospitals, with a 20% BPH hospital penetration rate[31] - The U.S. install base shows a shift from 1Q23 to 1Q25, with low-volume hospitals decreasing from 73% to 61%, medium-volume increasing from 6% to 8%, and high-volume increasing from 20% to 31%[30] Prostate Cancer & Aquablation Therapy - Approximately 60% of Active Surveillance patients will undergo radical treatment in 10-15 years[100] - In the U.S., 26% of localized prostate cancer diagnoses are high risk, 50% are intermediate risk, and 24% are low risk[79] - Early data from PRCT001 + PRCT002 trials includes 88 prostate cancer patients treated, with 65 having 3-month follow-up and 47 having 6-month follow-up[125] - 70% of prostate cancer patients in PRCT001 + PRCT002 have intermediate-risk disease[127] - 76% of patients in PRCT001 + PRCT002 have cancer in the Peripheral Zone[130]